Harrow, Inc. (NASDAQ:HROW) Shares Bought by AlphaQuest LLC

AlphaQuest LLC raised its position in Harrow, Inc. (NASDAQ:HROW) by 452.8% during the 4th quarter, according to its most recent filing with the SEC. The firm owned 3,527 shares of the company’s stock after buying an additional 2,889 shares during the quarter. AlphaQuest LLC’s holdings in Harrow were worth $118,000 as of its most recent filing with the SEC.

Other institutional investors also recently bought and sold shares of the company. Quest Partners LLC acquired a new position in Harrow in the 3rd quarter valued at $29,000. China Universal Asset Management Co. Ltd. increased its stake in Harrow by 10.7% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 7,552 shares of the company’s stock valued at $253,000 after buying an additional 727 shares during the period. Virtu Financial LLC acquired a new position in Harrow in the 3rd quarter valued at $271,000. Brookstone Capital Management acquired a new position in Harrow in the 4th quarter valued at $275,000. Finally, Bleakley Financial Group LLC increased its stake in Harrow by 63.1% in the 4th quarter. Bleakley Financial Group LLC now owns 8,770 shares of the company’s stock valued at $294,000 after buying an additional 3,394 shares during the period. 72.76% of the stock is owned by institutional investors and hedge funds.

Harrow Price Performance

Shares of NASDAQ HROW opened at $26.98 on Wednesday. Harrow, Inc. has a one year low of $9.30 and a one year high of $59.23. The company has a debt-to-equity ratio of 3.23, a quick ratio of 1.44 and a current ratio of 1.55. The company’s fifty day moving average is $30.01 and its two-hundred day moving average is $38.63. The firm has a market capitalization of $960.89 million, a P/E ratio of -28.70 and a beta of 0.69.

Analyst Upgrades and Downgrades

HROW has been the topic of several research analyst reports. B. Riley decreased their target price on shares of Harrow from $73.00 to $69.00 and set a “buy” rating on the stock in a research report on Wednesday, December 4th. HC Wainwright restated a “buy” rating and set a $57.00 target price on shares of Harrow in a research report on Tuesday.

About Harrow

Harrow, Inc operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc and changed its name to Harrow Health, Inc in December 2018. Harrow Health, Inc was incorporated in 2006 and is headquartered in Nashville, Tennessee.